North Central Cancer Treatment Group

描述（由申请人提供）：中北部癌症治疗小组（NCCTG）的具体目标是：1。通过开展高质量的多学科癌症治疗试验，提高癌症患者的生存时间和生活质量；2 .结合临床试验开展相关的实验室研究，提高对癌症生物学和治疗生物学后果的认识。3 .通过分析与临床结果相关的患者、肿瘤和治疗变量，改进进行临床试验的方法；为癌症预防和症状管理的研究提供基础设施。这些目标是通过四个疾病委员会（乳腺癌、胃肠癌、肺癌和神经肿瘤学）、三个以学科为导向的科学委员会（新疗法、生活质量和癌症控制）、三个模式委员会（外科、放射肿瘤学和病理学）、统计学和五个核心功能委员会（审计、肿瘤护理委员会、临床研究助理（CRA）委员会、癌症健康差距和患者倡导者）的努力实现的。疾病委员会负责与模式委员会、学科导向科学委员会和核心功能委员会合作，为各自的疾病实体开发和实施临床和转化研究。模式委员会向疾病和以学科为导向的科学委员会提供科学专门知识，制定质量控制标准并为个别研究提供质量控制，促进成员教育并开展适合其专业的研究。以学科为导向的科学委员会向疾病和模式委员会提供科学专门知识，并开展适合各自学科的研究。核心职能委员会协助制定适合其专业领域的协议、行为和质量保证。集团统计学家指定一名特定的统计学家与每个委员会持续合作，在意向书和概念发展、研究设计、数据收集、分析、介绍和出版方面进行合作。鉴于临床和转化癌症研究的多学科性质，为了实现该小组的科学目标，这些委员会之间有必要进行有效的沟通和互动。NCCTG内部这些相互作用的框架见表1，并在各个委员会的研究计划中进行了更详细的描述。NCCTG的首要科学任务是开展适合社区肿瘤学环境的高质量II期和iii期临床和转化研究。转译研究协调委员会为集团领导层提供咨询服务，包括NCCTG委员会领导人。该委员会的目的是为其他委员会进行的转化研究的发展和实施提供科学和技术咨询。转化研究协调概念的成员审查概念提案和方案，以评估其科学价值，推荐可能适合特定方案的额外转化目标，提供有关适当实验室方法的建议，并确定单个委员会之间的新主题，这些主题将导致各个委员会之间的合作。Wilma Lingle博士是NCCTG生物标本资源中心的联合主任，她也在转化研究协调委员会任职，并以翻译为目标审查概念和方案，提供有关适当标本收集、处理技术和运输的建议。

Description (provided by applicant): The specific aims of the North Central Cancer Treatment Group (NCCTG) are: 1. to improve the duration and quality of life of cancer patients by performing high-quality multidisciplinary cancer treatment trials, 2. to improve the understanding of cancer biology and the biological consequences of treatment by conducting relevant correlative laboratory studies in conjunction with the clinical trials, 3. to improve methods for performing clinical trials by analysis of patient, tumor, and treatment variables in association with clinical outcomes, and 4. to provide an infrastructure for studies of cancer prevention and symptom management. These aims are accomplished through the efforts of four Disease Committees (Breast Cancer, Gastrointestinal Cancer, Lung Cancer, and Neuro-oncology), three Discipline-oriented Scientific Committees (Novel Therapeutics, Quality of Life, and Cancer Control), three Modality Committees (Surgery, Radiation Oncology, and Pathology), Statistics, and five Core Function Committees (Audit, Oncology Nursing Board, Clinical Research Associate (CRA) Board, Cancer Health Disparities, and Patient Advocate). The Disease Committees are responsible for developing and implementing clinical and translational research studies for their respective disease entities in collaboration with Modality, Discipline-oriented Scientific, and Core Function Committees. Modality Committees provide scientific expertise to Disease and Discipline-oriented Scientific Committees, develop quality control standards and provide quality control for individual studies, promote member education and conduct research studies appropriate for their specialty. Discipline-oriented Scientific Committees provide scientific expertise to Disease and Modality Committees and conduct research studies appropriate for their respective disciplines. Core Function Committees assist in protocol development, conduct, and quality assurance appropriate to their areas of expertise. The Group Statistician designates a specific statistician to work with each committee on an ongoing basis to collaborate in letter of intent and concept development, study design, data collection, analysis, presentation and publication. Given the multidisciplinary nature of clinical and translational cancer research, productive communication and interactions among these committees is necessary in order to reach the scientific goals of the Group. The framework for these interactions within NCCTG is illustrated in Table 1, and is described in more detail within the research plans of individual committees. The overarching scientific priority for NCCTG is to conduct high-quality phase II and phase IIII clinical and translational studies appropriate for the community oncology setting. The Translational Research Coordinating Committee serves in an advisory capacity to Group leadership, including NCCTG Committee leaders. The purpose of the committee is to provide scientific and technical advice related to the development and implementation of translational research studies conducted by other committees. Members of the Translational Research Coordinating Concept review concept proposals and protocols in order to assess their scientific merit, recommend additional translational objectives that may be appropriate for a particular protocol, provide advice regarding appropriate laboratory methodology, and identify emerging themes among individual committees that will lead to collaborations among separate committees. Dr. Wilma Lingle, co-director of the NCCTG Biospecimen Resource, also serves on the Translational Research Coordinating Committee and reviews concepts and protocols with translational aims to provide advice concerning appropriate specimen collection, processing techniques, and transport.